AbbVie to Showcase New Data at the United European Gastroent

AbbVie today announced new data on the investigational use of risankizumab  in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA ® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5 . AbbVie is presenting a total of 13 abstracts, across a broad range of studies in IBD, including two ...

Related Keywords

Japan , Calgary , Alberta , Canada , Japanese , Chiedzo Mpofu , Remo Panaccione , Ann Gastroenterol , Gastroenterol Hepatol , Abbvie Ltd , Twitter , European Commission , Boehringer Ingelheim , Drug Administration , Exchange Commission , University Of Calgary , European Union , Allergan , Facebook , Abbvie Deutschland Gmbh Co , Crohn Colitis Foundation Of America , United European Gastroenterology , Week Virtual , Adapted Mayo Score , Disease Activity Index , Bowel Disease , Important Safety Information About , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Global Burden , Disease Study , European Gastroenterology Week Virtual , Inflammatory Bowel , Colitis Foundation , Rev Gastroenterol , Vie Deutschland Gmbh , Compare Safety , Adult Participants With Moderate , Severe Atopic Dermatitis , Evaluate Efficacy , Adult Participants With Axial Spondyloarthritis , Placebo Controlled Study , Endoscopic Remission , Subjects With Moderately , Severely Active Crohn , Disease Who Have Inadequately Responded , Are Intolerant , Participants With Moderately , Severely Active Ulcerative Colitis , Participants With Giant Cell Arteritis , Subjects With Takayasu Arteritis , Participants With Crohn , Study Comparing Risankizumab , Inadequate Response , Biologic Therapy , Placebo Controlled Induction Study , Severely Active Ulcerative ,